14 October 2021  
EMA/537752/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Skyrizi 
risankizumab 
On 14 October 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Skyrizi. The marketing authorisation holder for this medicinal product is AbbVie Deutschland GmbH & Co. 
KG. 
The CHMP adopted a new indication2 as follows: 
Plaque Psoriasis 
Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are 
candidates for systemic therapy. 
Psoriatic Arthritis 
Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the 
treatment of active psoriatic arthritis in adults who have had an inadequate response or 
who have been intolerant to one or more disease-modifying antirheumatic drugs 
(DMARDs). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
 
 
 
